Clinical Trials
18 trialsNCT07062965 2026-05-06
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT05306340 2026-04-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT07407517 2026-02-12
POLARIS
Fudan University
Phase 3 Not yet recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT07024173 2026-01-26
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05065411 2024-02-26
VERU-024
Veru Inc.
Phase 3 Terminated
NCT05954442 2024-01-16
BCTOP-T-M03
Fudan University
Phase 3 Recruiting
NCT02137837 2021-01-28
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT02376985 2019-10-21
Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT
Comprehensive Support Project for Oncology Research
Phase 3 Completed
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT01007942 2017-04-05
BOLERO-3
Novartis
Phase 3 Completed
NCT01626222 2017-02-23
MACS2096
Novartis
Phase 3 Completed
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT00567554 2016-02-10
GeparQuinto
GBG Forschungs GmbH
Phase 3 Completed
NCT01773460 2016-02-10
Evelyn
GBG Forschungs GmbH
Phase 3 Terminated